$0.845
-0.015 (-1.81%)收盤時
ELUT 資訊
ELUT 事件
Elutia Sells SimpliDerm Business to Cellution for Up to $11M
Elutia announced the signing of a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11M. Elutia will receive $8M in cash at closing, along with up to $3M in technology transfer and commercial milestone payments over the next 18 months. Closing is expected to occur in the second half of 2026, subject to customary closing conditions. The divestiture completes Elutia's previously announced strategic process for SimpliDerm and focuses the company's resources on NXT-41x, its antibiotic-eluting biomatrix for plastic and reconstructive surgery. Under the terms of the agreement, Elutia will receive $8M in cash at closing, along with up to an additional $3M in technology transfer and commercial milestone payments payable over the next 18 months.
Elutia Grants 460,000 Equity Awards to Three New Employees
Elutia announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan. The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options. The Options vest 25% on the first anniversary of the vesting commencement date, with the balance vesting in equal monthly installments over the following three years. Vesting is subject to each recipient's continued employment through the applicable vesting date. The Options have an exercise price of $1.09 per share, the closing price of Elutia's common stock on the Nasdaq Capital Market on March 10, 2026, the grant date. The Options are subject to the terms and conditions of the Plan and the applicable stock option agreement.
Elutia Appoints Pete Ligotti as Chief Commercial Officer
Elutia announced the appointment of Pete Ligotti as Chief Commercial Officer. Ligotti will lead the commercialization for NXT-41x.
Elutia CEO Says EluPro Success Transforms Company
"The success of EluPro was transformational for Elutia," said Dr. Randy Mills, Chief Executive Officer. "It validated the technical and commercial capability of our drug-eluting platform and enabled us to enter plastic and reconstructive surgery, where complication rates in breast reconstruction remain unacceptably high. We enter 2026 with a strong balance sheet and the capital required to develop and commercialize NXT-41x. With an experienced team and a focused strategy, we are positioned to execute and advance our mission so that patients can thrive without compromise."
Elutia announces Q3 earnings per share of 19 cents, compared to a loss of 33 cents last year.
Reports Q3 revenue $3.3M vs. $3.6M last year. "Behind every breast reconstruction is a woman overcoming cancer," said Randy Mills, CEO of Elutia. "Incredibly, infection remains one of the biggest barriers to recovery, impacting 15-20% of reconstruction cases. Our antibiotic-eluting technology is designed to prevent infection from occurring in the first place. The Elutia CRU is laser-focused on this goal, fully resourced, and moving fast to deliver a game-changing solution that helps women everywhere thrive without compromise."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。